Treatment Information


Kidney (Renal) Cancer treatment details. Biologic therapy, Immunotherapy.

The Methodist Hospital Research Institute, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Houston, Texas
Treatments:Biologic therapy, ImmunotherapyHospital:The Methodist Hospital Research Institute
Date:Feb 2006


Patients: The phase I/II study involved a total of 52 patients with metastatic renal cell carcinoma.

Treatment: The treatment consisted of a combination of biological therapy (thalidomide) and immunotherapy (interleukin-2).

Toxicity: For phase I, toxicities included: grade 3/4 fluid retention and grade 3 constipation. For phase II, toxicities included: grade 4 fatigue and skin toxicities.

Results: Overall median survival was not reported. Survival for individual patients ranged from a low of 1 month (1 patient) to a high of over 45 months (1 patient).

Support: One of the authors has received a grant from Celegene Corporation. Celgene manufactures and/or markets thalidomide.

Correspondence: Robert J. Amato, D.O.